Summary of mRNA vaccines for the prevention and therapy of bacterial and viral infections
| mRNA vaccine | Infection type | References |
|---|---|---|
| M72/AS01 | Tuberculosis | [61] |
| BNT162b2 (Comirnaty) | COVID-19 | [62] |
| mRNA-1215 | Nipah virus | [63] |
| ID91* | Tuberculosis | [64] |
| 19ISP | Lyme disease | [65] |
| mRNA-1273 (Spikevax) | COVID-19 | [66–68] |
| VAL-506440 | Influenza | [69] |
* Tested in animal models
AIA and OAA: Conceptualization, Visualization, Investigation, Writing—original draft, Writing—review & editing, Validation. AMI, CMIA, and PKF: Investigation, Validation, Writing—original draft. II, BIO, and EOD: Investigation, Writing—original draft. PYN: Conceptualization, Validation, Writing—original draft, Investigation. OJO: Writing—review & editing, Validation, Supervision. MMA: Writing—review & editing, Validation, Supervision, Visualization. All authors read and approved the submitted version.
All authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.